Dow Up0.62% Nasdaq Up0.45%

ImmunoClin Corporation (IMCL)

4.00 0.00(0.00%) Oct 10
ProfileGet Profile for:
ImmunoClin Corporation
9107 Wilshire Boulevard
Suite 450
Beverly Hills, CA 90210
United States - Map
Phone: 888-267-1175
Fax: 888-270-0258

Index Membership:N/A
Full Time Employees:N/A

Business Summary 

Immunoclin Corporation provides comprehensive, clinical, and basic science research services to pharmaceutical, biotechnology, and food industries. It is involved in the research and development on products, such as MIRA, an algorithm to analyze the multi-variant data to identify people who are at risk of having heart attack; and GARD, a genetic test for multiple genetic polymorphisms associated with increased risk of the most common form of dementia. Immunoclin Corporation is also engaged in the research and development of PRIMALEUKIN, an antibacterial, anti-fungal, and antiviral agent, harnessing and amplifying the body’s own natural defense against, and recovery from, infection; DACTELLIGENCE, a technology and newly patented concept in bio-sensing to challenge detection platforms in multiple diagnostic fields; and GastroWellBeing, an immunological food supplement. The company was formerly known as Pharma Investing News, Inc. and changed its name to Immunoclin Corporation in December 2013. Immunoclin Corporation is headquartered in Beverly Hills, California.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on ImmunoClin Corporation

Key Executives 
Dr. Dorothy Helen Bray Ph.D., 58
Chief Exec. Officer, Pres and Director
Mr. James Scott Munro , 45
Chief Financial Officer, Principal Accounting Officer and Treasurer
Dr. Khadija Benlhassan , 39
Chief Scientific Officer and Director
Mr. Raymond C. Dabney , 49
Management Consultant
Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders